The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas

Judith Favier1,2,3,4*, Jean-Jacques Brière5,6,9, Nelly Burnichon1,2,3,4, Julie Rivière1,2,3,4, Laure Vescovo7, Paule Benit5, Isabelle Giscos-Douriez1,2, Aurélien De Reyniès7, Jérôme Bertherat3,8,13, Cécile Badoual3,9, Frédérique Tissier3,10, Laurence Amar11, Rosella Libe8, Pierre-François Plouin1,3,4,11,13, Xavier Jeunemaitre1,2,3,4,12, Pierre Rustin5, Anne-Paule Gimenez-Roqueplo1,2,3,4,12,13

1 INSERM, unit 970, Paris, France, 2 Collège de France, Paris, France, 3 Université Paris Descartes, Faculté de Médecine, Paris, France, 4 Paris-Cardiovascular research Center at HEGP, Paris, France, 5 INSERM, unit 676, Hôpital Robert Debré, Paris, France, 6 Université René Diderot, Faculté de Médecine, Paris, France, 7 Programme Cartes d’Identité des Tumeurs, Ligue Nationale Contre Le Cancer, Paris, France, 8 AP-HP, Hôpital Cochin, Département d’Endocrinologie, Paris, France, 9 AP-HP, Hôpital Européen Georges Pompidou, Service d’Anatomopathologie, Paris, France, 10 AP-HP, Hôpital Cochin, Service d’Anatomie pathologique, Paris, France, 11 AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, Paris, France, 12 Rare Adrenal Cancer Network-Corticomédullolésionnelle Tumeur Endocrine, Institut National du Cancer, Paris, France

Introduction

In 1930, the biochemist Otto Warburg proposed that cancer was caused by defects in oxidative phosphorylation (OXPHOS) or aerobic respiration in the mitochondria; this would force the cell to shift to an anaerobic energy generation process, glycolysis, despite aerobic conditions [1,2]. After being forgotten for decades, the Warburg effect is being reconsidered and is now the subject of increasing interest and analysis [3,4,5]. OXPHOS and glycolysis have been evaluated in numerous tumor types, including renal clear cell carcinoma (RCC) in which the majority of glycolytic enzymes are overexpressed and mitochondrial enzymes under-expressed relative to patient-matched normal kidney cortex [6]. The Von Hippel-Lindau (VHL) gene is inactivated in 80% of sporadic RCC, and was thus suspected to mediate this phenomenon. VHL is a tumor suppressor gene responsible for the VHL disease, a hereditary neoplastic syndrome characterized by a predisposition to RCC, retinal and central nervous system hemangioblastomas, pancreatic cysts and pheochromocytomas [7]. In vitro studies confirmed that the presence of the VHL protein was required for intact respiratory chain protein content and activities in RCC [8,9].

Pheochromocytomas (PH) or functional paragangliomas (PGL) are rare catecholamine-secreting tumors arising from the adrenal medulla or sympathetic nervous ganglia. Approximately 25–30% of these tumors occur in the context of a hereditary cancer syndrome [10], one third of which are caused by mutations in the VHL gene. The other forms are mediated by mutations in the RET proto-oncogene and the NF1, SDHB, SDHC, or SDHD tumor suppressor genes. SDHB, C and D genes encode three of the four subunits of succinate dehydrogenase (SDH), a mitochondrial enzyme, which catalyzes the oxidation of succinate into fumarate in the tricarboxylic acid (TCA) cycle, and feeds electrons to the ubiquinone pool in the respiratory chain. Identification of
mutations in SDH genes led to the first and unexpected demonstration of a tumor suppressor role for a metabolic enzyme (for review see [11,12]), implicating mitochondrial deficiencies in tumorigenesis, as first suggested by Otto Warburg 80 years earlier.

Transcription profiling of hereditary and sporadic primary PH/PGL revealed that tumors associated with VHL [13], and later SDH [14] mutations display diverse angiogenesis and hypoxia markers and reduced expression of components of the oxidative response and TCA cycle. A hypoxia-inducible transcription factor (HIF)-dependent decrease in SDHB protein expression has also been described, specifically in SDH- and VHL-related PH/PGL.

A common feature of SDH and VHL mutations is their capacity to mediate a pseudo-hypoxic response, i.e. the abnormal stabilization of HIFs under normoxic conditions. The pVHL protein is an E3 ligase recognition factor, and its key function is the ubiquitination and subsequent degradation of the α subunit of HIF-1 and -2 in normoxia [7]. Inactivation of SDH also leads to HIF stabilization, through the inhibition of their hydroxylation by prolyl-4-hydroxylases, necessary for their recognition by pVHL [15,16]. HIFs may be important for the molecular modulation of the Warburg effect: HIF-1α is a key regulator of glycolysis and induces the expression of glucose transporters, glycolytic enzymes and lactate dehydrogenase; it also mediates the expression of pyruvate dehydrogenase kinase 1, which inhibits the conversion of pyruvate to acetyl-CoA, thereby attenuating mitochondrial function and respiration (for review, see [17]).

In this study, we investigated whether there is an increased Warburg effect in VHL-related PH/PGL, mediated by the pseudo-hypoxic drive. We compared angiogenesis, mitochondrial metabolism and glycolysis in PH/PGL tissues from patients suffering from VHL disease and patients presenting mutations affecting the SDH, RET or NF1 genes.

**Results**

**Evaluation of HIFs Expression and Angiogenesis in PH/PGL**

First, we performed HIF-1α and HIF-2α immunohistochemistry to evaluate pseudohypoxia in inherited PH/PGL tissues (Fig. 1A). We did not detect the expression of either HIF-1α or HIF-2α in RET and NF1 tumors, although both these proteins were present in adjacent adrenal tissues (data not shown). A very weak HIF-1α nuclear labeling was observed in 5 out of 8 SDH-related and in only 1 out of 10 VHL-related tumors studied. In contrast, HIF-2α was expressed at a much higher level both in the nucleus and cytoplasm of tumor cells from all 8 SDH samples and 7 out of 10 VHL PH/PGL. An increase in HIF-2α mRNA expression has previously been reported in VHL PH/PGL [13]. We thus compared the expression of both HIFs using genome-wide expression micro-array in a population of 68 inherited PH/PGL (28 VHL, 9 NF1, 9 RET, 17 SDHB, 3 SDHD and 2 SDHC) (Fig. 1B and C). We observed that HIF-2α was indeed overexpressed in VHL and in SDH-related tumors, as compared to RET and NF1 ones (4.7 (p = 10⁻⁶) and 3.5-fold (p = 10⁻⁵) increase vs NF1, respectively). There was no difference in HIF-1α mRNA levels between the different types of tumors studied.

We then used CD34 immunohistochemistry to evaluate the vascular density in PH/PGL samples (Fig. 2A). Blood vessel density was 2.5 to 3.5-fold higher in VHL (p<0.05) and in SDH (p<0.01) related tumors than in RET and NF1-related tumors (Fig. 2B).

**Expression and Activity of the OXPHOS Complexes**

We then tested for the Warburg effect in inherited PH/PGL. We first analyzed the expression and activity of various complexes of the mitochondrial electron transport system by Western blotting using a cocktail of monoclonal antibodies optimized for the detection of one subunit of each of the five OXPHOS complexes (20 kDa subunit in Complex I, SDHB in Complex II, core 2 in Complex III, COX II in Complex IV and F1α in ATP synthase). Each subunit identified was found to be less abundant when the corresponding complex failed to assemble properly. SDHA protein was assayed independently in all PH/PGL. Proteins of complexes I to IV were less abundant in SDH- and VHL-mutated tumors than in PH/PGL harboring NF1 and RET mutations, but complex V was relatively similar in all patients (Fig. 3A).

![Figure 1. Pseudohypoxia in SDH and VHL-related PH/PGL.](image-url)
immunohistochemistry, we confirmed our recently described observation that SDHB protein expression was completely lost in tumor cells of SDH-related patients and noticeably reduced in VHL-tumors, while it was still present in vascular endothelial and smooth muscle cells (Fig. 3B) [18].

Succinate cytochrome c reductase activity (SCCR, complex II + III) was measured in tumor homogenates: individual SDHB and SDHA protein expression followed SDH enzymatic activity. Complex II+III electron transfer activity was abolished in SDH and substantially lower in VHL samples than in NF1 and RET tumors (Fig. 3C). The mean values of enzymatic activities revealed that SCCR activity was 80-fold lower in SDH tumors (p < 0.001) and 4-fold lower in VHL (p < 0.01) tumors than in RET and NF1 samples (Fig. 3D). Interestingly, SCCR enzymatic activity as measured on these frozen tumor tissues was inversely correlated to the vascularization quantified in the corresponding paraffin-embedded samples (Fig. 2C) [18].

Biochemical studies also revealed that cytochrome c oxidase (COX, complex IV) activity was approximately 3-fold lower in SDH (p < 0.01) and in VHL (p < 0.01) samples than in NF1 and RET tumors (Fig. 3E). Finally, we assayed quinol cytochrome C reductase (QCCR, complex III) activity in tumor homogenates. QCCR activity was also slightly lower in SDH and VHL tumors, but the difference was much smaller (1.3 and 1.8-fold lower, respectively, than in NF1 and RET tumors) and was not statistically significant (Fig. 3F).

Induction of Anaerobic Glycolysis in VHL-related PH/PGL

We then evaluated several aspects of anaerobic glycolysis in tumor tissues. Activation of the HIF pathway in SDH and VHL PH/PGL may be responsible for the stimulation of glycolysis and anaerobic fermentation. Using immunohistochemistry, we studied the glucose transporter Glut 1, a well-described HIF-1α target, but found that it was restricted to erythrocytes, and was not expressed in chromaffin cells within PH/PGL tissues (data not shown). We then assessed the expression of hexokinase-II (HKK-II), another HIF-1 target, responsible for the first step of glycolysis, i.e. glucose phosphorylation into glucose-6P. HKK-II is the predominant hexokinase isoform overexpressed in cancers that exhibit a Warburg effect [19]. Surprisingly, we observed that HKK-II was expressed in all VHL tumors but was at the threshold of detection in all RET, NF1 and SDH tumors (Fig. 4A). Likewise, we found that lactate dehydrogenase (LDH), which catalyses the last step of anaerobic glycolysis and can be used as an indicator of glycolytic activity [4], was twice as active in all VHL tumors (p < 0.01) than in NF1 and RET PH/PGL. LDH activity in SDH tissues was similar to that in RET and NF1 samples (Fig. 4B) and clearly distinguished VHL from non-VHL PH/PGL (p = 0.001).

Microarray Evaluation of Electron Transport and Glycolysis-Related Genes in Inherited PH/PGL

In order to validate these observations in a larger cohort, we performed genome-wide expression microarray analysis in a population of 68 inherited PH/PGL. We compared the expression profile of genes involved in OXPHOS in 28 VHL tumors with that of 40 non-VHL PH/PGL (9 NF1, 9 RET, 17 SDHB, 3 SDHD and 2 SDHC). Among the 127 genes studied (200 probe sets), 47 genes (57 probe sets) were differentially expressed in VHL samples (Welch’s t-test p < 0.01). With the exception of two genes (COX4I2 and NDUFA4L2), all genes were down-regulated in the VHL group. The expression profile of these 200 probe sets was then used to perform a clustering of the 68 tumors (Fig. 5A). Such an analysis allowed classifying patients into two groups; the first one included all VHL and SDH patients and the second one included all RET and NF1 patients. Interestingly, the first cluster could be divided into three subclusters, which separated SDH tumors in one hand, and VHL PH/PGL in the other hand. The expression profile of these 200 probe sets was also used to perform a principal component analysis on the 68 tumors and led to

Figure 2. Angiogenesis in SDH and VHL-related PH/PGL. (A) CD34 immunohistochemistry was performed to evaluate angiogenesis in all samples. Diaminobenzidin was used as a chromogen for detection (brown labeling). Calibration bar: 200 μm. (B) Quantification of vascular density showing an increased number of blood vessels in SDH, and VHL tissues. Data are means±SEM. *p<0.05, **p<0.01, ***p<0.001. (C) Correlation between vascular density and SCCR enzymatic values for individual patients. doi:10.1371/journal.pone.0007094.g002
classification of patients into three groups: SDH, VHL and RET/NF1 tumors (Fig. 5B).

Reductions in gene expression detected by microarray analysis were subtle, and differences never reached a two-fold decrease. In contrast, the two increased genes were strongly upregulated. COX4I2 was overexpressed 25- and 45-fold in SDH and VHL tumors vs NF1, respectively. NDUF4L2 was increased by 11- and 21-fold in SDH and VHL tumors vs NF1, respectively (Fig. 5C).

We performed the same analysis with genes involved in the glycolytic pathway. Among the 20 genes studied (38 probe sets), 19 genes (37 probe sets) were differentially expressed in VHL samples (Welch’s t-test p<0.01), including 16 upregulated genes (33 probe sets) in the VHL group. The expression profile of these 38 probe sets was used to perform a clustering of the 68 tumors and led to the division of patients into two clusters (Fig. 5A). The first one regrouped all non-VHL patients (SDH, NF1 and RET), while all VHL tumors were included in the second (except one VHL in the first cluster). Analysis of individual genes revealed a significant up-regulation of Glut1, Glut3, HXK-II, phosphofructokinase (PFK), enolase 1 (enol1), phosphoglycerate kinase 1 (PGK1), LDHA, pyruvate dehydrogenase kinase 1 (PDK1), monocarboxylate transporter 4 (MTC-4), phosphoglucomutase 1 (PGM1) in VHL versus non-VHL tissues. The average overexpression was between 2- to 4-fold, but reached 15- to 17-fold for HXK-II and the lactate transporter MTC-4, respectively. Interestingly, although SDH patients displayed levels of expression usually comparable to that observed in RET and NF1 tumors, Glut3, HXK-II and LDHA were also significantly overexpressed in this subset of patients (Fig. 6B).

Loss of p53 and TIGAR Expression in VHL-related PH/PGL

Glycolysis was stimulated in all VHL samples but not in SDH tumors, and it appeared that stimulation of the HIF pathway could...
not account for this phenomenon. Recently, the tumor suppressor p53 was revealed to be a new and unexpected target, stabilized and activated by pVHL [20]. p53 is a transcription factor that regulates the expression of TIGAR (TP53-induced glycolysis and apoptosis regulator), a protein displaying fructose-2,6-bisphosphatase activity, thereby lowering fructose-2,6-bisphosphate concentrations in cells, resulting in inhibition of glycolysis [21]. These findings suggest that anaerobic glycolysis may be stimulated in cells that lack functional p53. Microarray analysis in the 68 inherited tumors revealed a modest but significant decrease of TIGAR mRNA expression (0.7 fold, Welch T-test \( p < 0.05 \)) in VHL vs non-VHL tumors (Fig. 6B).

We thus evaluated the expression of p53 and TIGAR by immunohistochemistry in 20 available paraffin-embedded specimens (Fig. 7, Table 1). With the exception of 3 patients, cytoplasmic expression of TIGAR was systematically associated with the presence of p53 in the nucleus of tumor cells. Patients could be classified into two groups regarding TIGAR expression. A positive group displayed a widespread expression of TIGAR, either throughout the whole tumor sample or heterogeneously, with positive areas adjacent to TIGAR negative regions. A negative group showed no TIGAR labeling in tumor cells. The positive group comprised two NF1, one RET, six SDH and one VHL tumors. The negative group was composed of seven VHL, two SDH and one RET tumors. Loss of TIGAR expression thus appeared preferentially in VHL-related PH/PGL (\( p = 0.025 \)).

**Discussion**

Here, we show that PH/PGL susceptibility genes influence the complex cellular balance between angiogenesis, electron transport and glycolysis, which are regulated by two master genes, HIF and p53. Our results suggest that activation of the HIF pathway associated with the loss of p53 activity might mediate the molecular and biochemical features of the Warburg effect; this effect was clearly observed in VHL PH/PGL, but not in RET and NF1 and only partially in SDH tumors.

In accordance with the observations reported by Dahia et al [14], we observed an overall down-regulation of SDHB protein level and activity in SDH- and VHL-mutated tissues, but this was not specific to the SDHB subunit as it was associated with comparable decreases in SDHA expression and in SDH activity. Activation of HIFs is a major aspect of cancer biology [22] and has been associated with the Warburg effect. In VHL-deficient RCC cell lines, it was recently shown that HIF-1α inhibits mitochondrial respiration by activating MXI-1 transcription, which encodes a c-Myc repressor [23]. C-Myc inhibition leads to down-regulation of PCG-1β, a PPARγ-coactivator that has been implicated in mitochondrial biogenesis [24]. We therefore studied the expression and activity of other complexes of the respiratory chain. We found an overall decrease in subunits of complexes I to IV in tumors from SDH and VHL patients. Biochemical analyses showed a reduction in enzyme activities affecting the cytochrome c oxidase (COX; complex IV) and, also, but to a much lesser extent, quinol cytochrome c reductase (complex III). Again, such defects were not observed in tumors that retain the ability to degrade HIFs in normoxia (i.e. RET and NF1 tumors). Using transcriptome analysis, we confirmed these findings and showed that unsupervised analysis of gene expression in the OXPHOS pathway is highly efficient to classify patients depending on cancer-predisposing gene. However, for genes that were significantly
down-regulated in pseudo-hypoxic tumors, differences in mRNA expression were subtle, suggesting that regulation of mitochondrial respiration principally occurred at the post-traductional level. We performed MXI-1 and c-Myc immunohistochemistry (data not shown) and analyzed MXI-1 and PGC1-β mRNA expression by microarray, but such experiments led to negative results. There was no difference in their respective expression in the different types of hereditary PH/PGL, suggesting that the crosstalk between HIF and c-Myc pathways described in RCC or lymphoma cell lines [23,25], was not implicated in the decreased mitochondrial biogenesis observed in human PH/PGL tissues.

Interestingly, a recent study showed that HIF-1 tightly regulates the expression of the COX4-1 and COX4-2 subunits and of the LON mitochondrial protease, in such a way that conditions stabilizing HIF-1 lead to a decreased COX activity, which was interpreted by the authors as an optimization of respiration...
efficiency in hypoxia [26]. The microarray analysis we performed on 68 inherited PH/PGL confirmed the observations made in vitro in human tumor tissues. COX4-2 was drastically overexpressed in pseudo-hypoxic PH/PGL as compared to RET and NF1 tumors, while COX4-1 was decreased two-fold. These results provide a possible molecular mechanism for the decrease in COX activity observed in SDH and VHL tumors. The NDUFA4L2 transcript was also strongly overexpressed in PH/PGL harboring SDH and VHL mutations. Interestingly, this gene was identified as the first gene up-regulated in a transcriptome analysis of hypoxic neuroblastoma cells, another neural-crest derived tumor that shares a number of features with PH/PGL [27]. NDUFA4L2 encodes a protein homologous to the NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4, a subunit of mitochondrial complex I. Although the function of this protein is unknown, one could postulate that it may act as a COX4-1/COX4-2 switch,

Figure 6. Microarray analysis of glycolysis in hereditary PH/PGL. (A) Unsupervised hierarchical clustering analysis of the 68 samples according to the expression of 38 genes. Expression profiles are shown as a heat map indicating high (red) and low (blue) expression according to a log2-transformed scale. The different mutations are localized in three distinct clusters: SDH (grey), VHL (white) and RET/NF1 (black). (B) Mean values for genes expression between SDH, VHL, RET and NF1 tumors. Data are means±SEM, represented as relative to NF1 expression values. **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0007094.g006
limiting complex I activity in hypoxic tumors. Altogether, our observations demonstrate a reduced electron transport in some inherited PH/PGL and suggest that activation of the hypoxic response may be directly involved in the decreased mitochondrial respiration in these tumors.

One of the first described functions of the HIF pathway is activation of glycolysis; HIF-1α up-regulates the expression of most glycolytic enzymes and the glucose transporters GLUT1 and 3. As for vascularization and reduction in electron transport complexes, we thus expected to observe more active glycolysis in SDH and VHL PH/PGL than in RET and NF1 tumors. Most surprisingly, both expression of hexokinase II and the activity of lactate dehydrogenase were high in VHL patients, but not in SDH specimens. Transcriptome analysis confirmed the specific activation of glycolysis in VHL PH/PGL, indicating that such analysis was a powerful tool to discriminate VHL from non-VHL inherited PH/PGL. It is likely that in the case of an SDH defect, the cells might cope more easily with decreased ATP production by the mitochondria, as most of the respiratory chain will still be functional, and several metabolic shunts are potentially able to provide electrons and generate a membrane potential sufficient to generate normal levels of ATP. These observations were however unexpected, notably because positron emission tomography with 2-[(18)F]-fluoro-2-deoxy-D-glucose ([(18)F]-FDG PET) tracing glucose uptake was recently shown to be particularly sensitive for the evaluation of bone metastases in patients harboring SDHB mutations [28]. However, it is worth noting that, if whole glycolysis was not enhanced in SDH patients (as compared to RET or NF1), this subset of tumors did present a 4-fold increase in GLUT3 mRNA expression, as assessed by microarray. This augmentation would be sufficient to explain the high sensitivity of SDH tumors to [(18)F]-FDG PET and confirms that such approach is indeed relevant for the clinical evaluation of SDHB-related patients. The overexpression of mRNA encoding GLUT1 (7-fold), GLUT3 (4-fold) and HXK-II (15-fold) in VHL PH/PGL suggests that sensitivity for [(18)F]-FDG PET should be evaluated in these patients, where it is expected to be highly effective.

One possible explanation for the discrepancy observed between VHL and SDH tumors for the rest of the glycolytic pathway arises

Table 1. Expression of p53 and TIGAR in inherited PH/PGL evaluated by immunohistochemistry.

| Patient No | Gene mutated | TIGAR | p53 |
|------------|--------------|-------|-----|
| P11        | RET          | +     | −   |
| P20        | RET          | −     | −   |
| P12        | NF1          | +     | +   |
| P19        | NF1          | +     | +   |
| P9         | SDHD         | +     | +   |
| P10        | SDHB         | +     | +   |
| P22        | SDHB         | +     | +   |
| P23        | SDHB         | −     | +   |
| P24        | SDHD         | −     | +   |
| P25        | SDHB         | +     | +   |
| P26        | SDHD         | +     | +   |
| P27        | SDHC         | +     | +   |
| P6         | VHL          | −     | −   |
| P7         | VHL          | −     | +   |
| P14        | VHL          | −     | −   |
| P16        | VHL          | −     | −   |
| P18        | VHL          | −     | −   |
| P3         | VHL          | −     | −   |
| P4         | VHL          | −     | −   |
| P5         | VHL          | +     | +   |

TIGAR is absent from 7 of 8 VHL tumor tissues, but was detected in 9 of 12 RET, NF1 and SDH tumors.

doi:10.1371/journal.pone.0007094.t001

Figure 7. Representative expression of p53 and TIGAR in PH/PGL. Immunohistochemistry revealed a mild to strong nuclear p53 labeling, and the cytoplasmic expression of TIGAR in the majority of RET, NF1 and SDH tumors. Such labeling was only detected in 2 out of 9 VHL tumor tissues (data not shown). In most VHL PH/PGL p53 protein and its target TIGAR were hardly detectable. Calibration bar: 50 μm.

doi:10.1371/journal.pone.0007094.g007
from the capacity of HIF-1α and HIF-2α to regulate the expression of different target genes: HIF-1α is the transcription factor involved in hypoxic induction of glycolysis but HIF-2α does not seem to participate in this process [29]. Pollard et al. recently reported the immunohistological analysis of HIFs factors in VHL and SDH-related PH/PGL [30]. They described a relatively higher expression of HIF-2α than HIF-1α in VHL tumors and a reverse pattern in SDH tumors. Surprisingly, in our subset of tumors, we observed high HIF-2α and low HIF-1α expression in both SDH and VHL PH/PGL. The reason for this discrepancy remains to be addressed and may be dependent on patients or, although unlikely, on experimental conditions. On the other hand, the predominance of HIF-2α is supported by previous observations performed in fetal paraganglia and neuroblastoma [31–33] and by its upregulation at mRNA level in both VHL and SDH PH/PGL. It could explain the absence of hypoxia-mediated activation of the glycolytic response in these tumors. It thus appears that the stimulation of glycolysis in VHL-PH/PGL is not fully mediated by activation of the HIF pathway, but also depends on an additional function of pVHL.

Recently, Roe et al. identified p53 as a new and unexpected target of pVHL [20]. Unlike its activity on HIF proteins, VHL binding to p53 suppresses Mdm2-mediated ubiquitination and nuclear export and thereby leads to p53 stabilization. pVHL also binds ATM and p300 to favor their stabilizing and activating properties on p53. Loss of p53 has recently been associated with mitochondrial and glycolytic metabolism. It can physically localize to mitochondria where it causes mitochondrial DNA depletion and altered reactive oxygen species homeostasis [34]. As a nuclear transcription factor, it activates the expression of SCO2 [35] and TIGAR [21], respectively implicated in the COX multimeric protein complex assembly required for OXPHOS and in inhibition of glycolysis. It therefore seemed plausible that p53-dependant loss of TIGAR in VHL-mutated samples may explain the activation of glycolysis specifically observed in these tissues. In normal cells, nuclear p53 expression is usually below the detection level of immunohistochemistry. Mutant p53, because of its longer half-life can result in positive nuclear immunostaining. In the present study, we were unable to detect p53 in PH/PGL samples using a standard immunohistochemistry protocol. This observation is in accordance with most reported studies that showed very little p53 mutations in benign PH/PGL [36–38]. However, using tyramide signal amplification, we were able to reveal p53 expression in tumor tissues. We confirmed that TIGAR protein was absent from 7/8 VHL-PH/PGL samples analyzed, but was present in 9/12 non-VHL samples. These observations are the first in situ demonstration of the link between VHL inactivation and loss of the p53-TIGAR pathway in a human tumor. They provide a pertinent explanation for the specific activation of glycolysis in VHL-related PH/PGL.

In conclusion, our data establish the occurrence of a Warburg effect specifically in PH/PGL harboring a VHL germ-line mutation. Analysis of the underlying mechanism suggests that this phenomenon depends on the activation of the pseudo-hypoxic pathway — most probably mediated by the abnormal stabilization of HIF-2α following VHL inactivation — and the loss of the p53/TIGAR pathway. Together, these phenomena concur to the observed decreased electron transport and increased glycolysis. In SDH tumors, where p53 loss is not expected nor detected, activation of whole glycolysis was not observed. Finally, in RET and NF1 tumors, which are neither related to an activation of the HIF pathway nor to a loss of p53, we did not observe any of the metabolic or angiogenic inductions discernible in VHL tumors. These results thus provide a direct insight into the mechanisms underlying tumorigenesis in VHL-related PH/PGL and their links with metabolic disorders.

Materials and Methods

Patients
We first analyzed 26 tumors collected by the COMETE network from 25 patients (11 men, 14 women) operated on between 1994 and 2005, in two tertiary referral centers in Paris: the Hypertension Unit in Hôpital Européen Georges Pompidou and the Department of Endocrinology in Hôpital Cochin. Twenty were pheochromocytomas and 6 were functional extra-adrenal paragangliomas. The procedures used for PH/PGL diagnosis and genetic testing were in accordance with institutional guidelines and have been described previously [10,39]. The associated syndromic lesions and the family history of each case are described in Table 2. Two patients had a NF1 phenotype. The genetic testing identified a germ-line RET mutation in three patients, an SDHB mutation in five patients, an SDHD mutation in two patients, an SDHC mutation in one patient and a VHL missense mutation in 12 patients. A large deletion in VHL from exon 1 to exon 3 was detected in one patient by the QMPSF method [39]. For each patient, we obtained two or three frozen samples and two paraffin-embedded specimens prepared for routine pathological analyses.

For microarray studies, 42 additional patients with hereditary PH/PGL were recruited for a total of 68 tumors studied (see Table 3 for clinical characteristics of patients).

Ethics Statement
Informed signed consent for germline and somatic DNA analysis was obtained from each patient recruited by the COMETE network, and the study was formally approved by an institutional review board (CPP Paris-Cochin).

Immunohistochemistry
Paraffin blocks were cut and sections (6-micrometers thick) were mounted on Superfrost plus slides and used for immunohistochemistry as previously described [31]. The protocol involved a biotinylated secondary antibody (Vector Laboratories), an avidin-biotin-peroxidase complex (Vectastain ABC Elite; Vector Laboratories) and diamino-benzidin (Vector Laboratories) or Histogreen (Abcys) as chromogens for the peroxidase activity. Antibodies were as follows: HIF-1α (H1A07, abcam, 1/500), HIF-2α (ab1199, abcam, 1/1000), CD34 (Clone QBEND 10, Immunotech, 1/100), 9-actin (#10581, Dako, 1/1000), SDHB (HPA002868, Sigma-Aldrich, 1/500), Glut1 (Labvision, 1/200), p33 (Ab-8, Neomarkers 1/1000), TIGAR (abcam, 1/200). p53 expression was revealed using the Tyramide Signal Amplification (TSA) System (Perkin Elmer). Heat-mediated antigen retrieval was performed for p53, Glut1, SDHB and TIGAR (10 mM citrate buffer, pH 6, 15 min), and for HIF-1α and HIF-2α (Tris 100 mM, EDTA 1 mM, 0.05% Tween, pH 9, 45 min).

Quantification of Vascular Density
Vascular density was measured on sections after CD34 immunostaining on the two independent samples obtained from each patient. For each sample, total blood vessels were counted in eight randomly chosen fields of 0.125 mm². For one patient (P0), vascular density could not be evaluated because of an anarchic vascular architecture.

Western Blotting
Frozen tissues were lysed in protein extraction buffer (25 mM Tris, 100 mM NaCl, 0.5% NP40, 0.5% deoxycholic acid, 5 mM EDTA, protease inhibitor cocktail (Sigma)).
Aliquots of 50 mg of protein were separated on SDS-PAGE denaturing gels and transferred to either PVDF (Immobilon-P, Millipore) for SDHB, SDHA and OXPHOS experiments or nitrocellulose membranes (Hybond-ECL, Amersham Biosciences) for p53 and HKX-II experiments. Ponceau staining confirmed equivalent loading of each sample and membranes were then blocked in 5% milk in TBST buffer, and probed with the primary antibody.

### Table 2. Clinical features of the patients studied.

| Tumor ID | Tumor type | Hereditary PH/PGL type | Gene | Mutation | Sex | Age at surgery (years) | Tumor size (mm) | Clinical characteristics | Familial characteristics |
|----------|------------|------------------------|------|----------|-----|------------------------|-----------------|------------------------|-------------------------|
| P11      | PH         | MEN2                   | RET  | A883F    | F   | 57                     | 25              | bilateral PH, MTC, marfanoid habitus |
| P20      | PH         | MEN2                   | RET  | C634R    | F   | 29                     | 32              | bilateral PH, MTC, MEN-2 family’s history |
| P12      | PH         | neurofibromatosis type 1 | NF1  | ND       | F   | 32                     | 25              | unique PH, “café-au-lait” spots, Lisch nodules, scoliosis |
| P19      | PH         | neurofibromatosis type 1 | NF1  | ND       | F   | 32                     | 50              | unique PH, “café-au-lait” spots, Lisch nodules, neurofibromatosis |
| P21      | PH         | neurofibromatosis type 1 | NF1  | ND       | F   | 39                     | 35              | unique PH, “café-au-lait” spots, Lisch nodules |
| P9       | EA FPGL    | hereditary paraganglioma | SDHD | R22X     | M   | 61                     | 22              | EA abdominal and bilateral carotid PGL |
| P10      | EA FPGL    | hereditary paraganglioma | SDHB | L207fs   | M   | 37                     | 70              | EA bladder PGL |
| P22      | PH         | hereditary paraganglioma | SDHB | P56TyrfsX5 | F   | 20                     | 52              | unique PH |
| P23      | PH         | hereditary paraganglioma | SDHB | C253Y    | F   | 21                     | 110             | unique PH |
| P24      | EA PGL     | hereditary paraganglioma | SDHB | F238SerfsX10 | F   | 10                     | 40              | unique PGL |
| P25      | PH         | hereditary paraganglioma | SDHB | R46G     | F   | 31                     | 35              | Unique PH |
| P26      | EA PGL     | hereditary paraganglioma | SDHD | R22X     | M   | 32                     | 35              | Thoracic PGL, carotid PGL; Father: bilateral carotid PGL; brother: bilateral neck PGL |
| P27      | EA PGL     | hereditary paraganglioma | SDHC | del exon 2 | F   | 16                     | 45              | unique PGL |
| P1       | PH         | von Hippel Lindau      | VHL  | Complete deletion | M   | 32                     | 30              | unique PH, cerebellar and bulbar HB |
| P2       | PH         | von Hippel Lindau      | VHL  | S80I     | M   | 33                     | 30              | bilateral PH, retinal and cerebellar HB, pancreatic kyst |
| P8/16    | EA FPGL    | von Hippel Lindau      | VHL  | R161Q    | F   | 24                     | 30              | multiple EA abdominal PGL, bilateral PH, renal kyst |
| P6       | PH         | von Hippel Lindau      | VHL  | R167Q    | M   | 26                     | 55              | unilateral PH, retinal and cerebellar HB, renal cancer |
| P7       | PH         | von Hippel Lindau      | VHL  | L178P    | M   | 15                     | 30              | bilateral PH, carotid PGL; P17’s cousin; uncle: bilateral PH, renal cancers, bulbar HB |
| P14      | PH         | von Hippel Lindau      | VHL  | Y98H     | F   | 29                     | 30              | bilateral PH; P18’s daughter; aunt: unique PH, cervical and thoracic PGL |
| P17      | PH         | von Hippel Lindau      | VHL  | L178P    | M   | 13                     | 50              | bilateral PH; P7’s cousin; father: bilateral PH, renal cancers, bulbar HB |
| P18      | PH         | von Hippel Lindau      | VHL  | Y98H     | M   | 51                     | 30              | unique PH, retinal HB, renal cancer; P14’s father; sister: unique PH, cervical and thoracic PGL |
| P3       | PH         | von Hippel Lindau      | VHL  | Y156C    | M   | 18                     | 30              | unique PH, no renal cancer, no HB; mother: unique PH, no renal cancer, no HB |
| P4       | EA FPGL    | von Hippel Lindau      | VHL  | Y156C    | M   | 20                     | 25              | EA abdominal PGL, no renal cancer, no HB; mother: bilateral PH, vagal PGL, no renal cancer, no HB |
| P5       | PH         | von Hippel Lindau      | VHL  | P97L     | F   | 17                     | 30              | unique PH, no renal cancer, no HB; brother: bilateral PH, no renal cancer, no HB |
| P13      | PH         | von Hippel Lindau      | VHL  | Y156H    | F   | 65                     | 40              | bilateral PH, multiple EA PGL, no HB, no renal cancer |

PH/PGL: pheochromocytoma/paraganglioma; EA FPGL: extra-adrenal functional paraganglioma; MTC: medullary thyroid carcinoma; HB: hemangioblastoma

doi:10.1371/journal.pone.0007094.t002
Antibodies used for western blot experiments were as follows: SDHB (Molecular Probes, 1/1000), Oxphos complexes kit (MitoSciences, 1/200), SDHA (Molecular Probes, 1/1000), SDHB (Molecular Probes, 1/1000), Oxphos complexes kit 1/400) and succinate cytochrome c oxidase (Amersham Biosciences). Bound antibodies were visualized using ECL Plus reagent linked secondary antibodies (Amersham Biosciences, 1/5000), and Melbourne, Australia [40].

Assessment of Mitochondrial Respiratory Chain Function and Enzyme Assay

Activities of cytochrome c oxidase (COX; complex IV), succinate cytochrome c reductase (SCGR; complexes II+III), quinol cytochrome c reductase (QCCR; complex III) and lactate dehydrogenase were measured spectrophotometrically using a pseudo dual-wavelength Cary 50 spectrophotometer (Varian, Melbourne, Australia) [40].

Microarray

Tumor samples (20 to 30 mg) were powdered under liquid nitrogen. RNAs were extracted using RNeasy mini kit (Qiagen). Aliquots of the RNA were analyzed by electrophoresis on a Bioanalyser 2100 (Agilent Technologies) and quantified using Nano Drop ND-1000 (Labtech). Stringent criteria for RNA quality were applied to rule out degradation, especially a 28 s/18 s ratio above 1.5. Microarray analyses were performed using 3 µg of total RNA of each sample as starting material and 10 µg cRNA per hybridization (GeneChip Fluidics Station 400; Affymetrix, Santa Clara, CA). The total RNA were amplified and labeled following the manufacturer’s one-cycle target labeling protocol (http://www.affymetrix.com). The labeled cDNA were then hybridized to HG-U133 Plus 2.0 Affymetrix GeneChip arrays (Affymetrix). The chips were scanned with a GCOS 1.4.

Statistical Analysis

Statistical analyses were performed using the Stat View software (SAS Institute Inc.). Differences were evaluated by ANOVA Bonferroni Test. A p value <0.05 was considered statistically significant. Microarray analyses were performed with R system software (http://www.R-project.org, V2.3.0) including packages of Bioconductor [41]. Raw feature data from Affymetrix HG-U133 Plus 2.0 GeneChip™ microarrays were normalized using robust multi-array average (RMA) method (Bioconductor package affy) [42]. We used Welch’s t-tests to identify genes differentially expressed between groups of samples (R package stats). Clustering were performed using Ward linkage and (1-Pearson coefficient of correlation) as inter-individual distance (R package cluster). Principal component analysis was performed using the function pamr (R package stats).

Genes from the KEGG pathway ‘Oxidative phosphorylation’ (hsa00190) were obtained from (http://www.genome.ad.jp/kegg/kegg2.html). The glycolysis pathway genes comprised glucose transporters, glycolytic enzymes, lactate dehydrogenase and lactate transporter, as well as TIGAR.

Acknowledgments

We express our gratitude to Jean-Marie Gasc, Xavier Ituriez, Annie Michael and Jorge Gallego for helpful discussions, as well as Fernande Rene-Coral and Tchao Meatchi for technical assistance. We thank, the GIS-Institut des Maladies Rares for the PGL.NET Network and the COMETE network for support.

Author Contributions

Conceived and designed the experiments: JF PR APGR. Performed the experiments: JJB NB PB PR. Analyzed the data: JF JJB LV AdR XJ PR. Wrote the paper: JF PR APGR. EXPANSION articles/analysis tools: JB CB FT LA RL FPB APGR. PFP APGR. Wrote the paper: JF PR APGR.

References

1. Warburg O (1930) Ueber den stoffwechsel der tumoren. Constable, London.
2. Warburg O (1936) On respiratory impairment in cancer cells. Science 124: 269–270.
3. Rustin P, Kroemer G (2007) Mitochondria and cancer. Ernst Shering Res Found Workshop 62.
4. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029–1033.
5. Craven RA, Stanely AJ, Hanrahan S, Doh J, Unwin R, et al. (2006) Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 6: 2853–2864.
6. Kim WY, Kaern WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991–5004.
7. Kim WY, Kaern WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991–5004.
8. Herouet E, Demont J, Pocina P, Vojtiskova A, Houstek J, et al. (2005) A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 26: 531–539.
9. Craven RA, Stanley AJ, Hanrahan S, Doh J, Unwin R, et al. (2006) Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 6: 2853–2864.
10. Amar L, Berthierat J, Baudin E, Aujenberg C, Bressac-de Paillerets B, et al. (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 22: 4991–5004.
11. Favier J, Briere J, Strompf L, Amar L, Filali M, et al. (2005) HEREDITY paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Horm Res 63: 171–179.
12. King A, Selak MA, Gottlieb E (2006) Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25: 4673–4682.
13. Eisenhoffer G, Huyh TT, Pacak K, Brouwers FM, Wàhler MM, et al. (2004) Distinct gene expression patterns in tumor and epithelium-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 11: 897–911.
14. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, et al. (2005) A HIF-1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1: 72–80.
15. Briere JJ, Favier J, Benit P, El Ghouzzi V, Lorrenzo A, et al. (2005) Mitochondrial saccine is instrumental for HIF-1alpha nuclear translocation in SDH-deficient fibroblasts under normoxic conditions. Hum Mol Genet 14: 3263–3269.
16. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, et al. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7: 77–85.
17. Yeung SJ, Pan J, Lee MH (2008) Roles of p53, MYC and HIF-1 in regulating glycolysis: the seventh hallmark of cancer. Cell Mol Life Sci 65: 3981–3999.
18. van Nederveen FH, Gaal J, Favier J, Kopershtok E, Oldenburg RA, et al. (2009) An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol.
19. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to HIF-1alpha regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129: 111–122.
20. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, et al. (2006) p53 stabilization and action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat cell differentiation. Cell Metab 3: 333–341.
21. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, et al. (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107–120.
22. Yeung SJ, Pan J, Lee MH (2008) Mitochondrial biogenesis and fumarate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas. J Endocrinol 159: 247–255.
23. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, et al. (2007) HIF-1alpha inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407–420.
24. Uldry M, Yang W, St-Pierre J, Lin J, Seale P, et al. (2006) Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab 3: 333–341.
25. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV (2007) Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic shifts hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 27: 7381–7393.
26. Fukuda R, Zhang H, Kim JW, Shimoda I, Dang CV, et al. (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129: 111–122.
27. Fukuda R, Zhao H, Tang X, Shi J, Dang CV, et al. (2007) Transcriptional adaptation of neuroblastoma cells to hypoxia. Biochem Biophys Res Commun 366: 1054–1060.
28. Zelinka T, Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, et al. (2008) Role of p53 expression tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer 15: 311–323.
29. Hu CJ, Iyer S, Sataur A, Covello KL, Chodosh LA, et al. (2006) Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol 26: 3514–3526.
30. Pollard PJ, El-Bahrawy M, Poulemon K, Elia G, Killick P, et al. (2006) Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 91: 4593–4600.
31. Favier JF, Kempf H, Corvol P, Gaet J (1999) Cloning and expression pattern of EPAS1 in the chicken embryo. Colocalization with tyrosine hydroxylase. FEBS Lett 462: 19–24.
32. Nilsson H, Jeng A, Beckman S, Harris AL, Poellinger L, et al. (2005) HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp Cell Res 303: 447–456.
33. Tian H, Hamner RE, Matsumoto AM, Russell DW, Mc-Knight SL (1998) The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12: 3320–3334.
34. Lebedeva MA, Eaton JS, Shadel GS (2009) Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim Biophys Acta 1787: 328–334.
35. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, et al. (2006) p53 regulates mitochondrial respiration. Science 312: 1650–1653.
36. Herfarth KK, Wick MR, Marshall BN, Gartner E, Lamm S, et al. (1997) Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas. Genes Chromosomes Cancer 20: 24–29.
37. Petri BJ, Speel EJ, Kopershtein E, Claessen SM, van Nederveen FH, et al. (2008) Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas. Mod Pathol 21: 407–413.
38. Yoshimoto T, Naruse M, Zeng Z, Nishikawa T, Kasagima T, et al. (1998) The relatively high frequency of p53 gene mutations in multiple and malignant pheochromocytomas. J Endocrinol 159: 247–255.
39. Amar L, Baquin E, Burriehon N, Peyraud S, Silveria S, et al. (2007) Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92: 3822–3828.
40. Benit P, Goncalves S, Philippe Dassa E, Briere JJ, Martin G, et al. (2006) Three spectrophotometric assays for the measurement of the five respiratory chain complexes in minuscule biological samples. Clin Chim Acta 374: 81–86.
41. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
42. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249–264.